Advanced Search
SHAO Bin, ZHANG Jie, LV Min, ZHU Yulin, YU Jing, JIANG Hanfang, REN Jun, SONG Guohong, ZHU Budong, CHE Li, JIA Jun, LIANG Xu, WANG Chaoying, YAN Ying, LIN Xiaolin, HUANG Xiaolei, YOU Miaoning, WANG Xiaoli, ZHOU Xinna, DI Lijun. Effects of High-dose Chemotherapy Supported by Autologous Peripheral Blood Stem Cell on Quality of Life of Advanced Breast Cancer Patients[J]. Cancer Research on Prevention and Treatment, 2015, 42(02): 145-149. DOI: 10.3971/j.issn.1000-8578.2015.02.010
Citation: SHAO Bin, ZHANG Jie, LV Min, ZHU Yulin, YU Jing, JIANG Hanfang, REN Jun, SONG Guohong, ZHU Budong, CHE Li, JIA Jun, LIANG Xu, WANG Chaoying, YAN Ying, LIN Xiaolin, HUANG Xiaolei, YOU Miaoning, WANG Xiaoli, ZHOU Xinna, DI Lijun. Effects of High-dose Chemotherapy Supported by Autologous Peripheral Blood Stem Cell on Quality of Life of Advanced Breast Cancer Patients[J]. Cancer Research on Prevention and Treatment, 2015, 42(02): 145-149. DOI: 10.3971/j.issn.1000-8578.2015.02.010

Effects of High-dose Chemotherapy Supported by Autologous Peripheral Blood Stem Cell on Quality of Life of Advanced Breast Cancer Patients

More Information
  • Received Date: October 28, 2013
  • Revised Date: May 01, 2014
  • Objective To analyze the quality of life (QOL) of advanced breast cancer patients after receiving high-dose chemotherapy supported by autologous peripheral blood stem cells, and to provide evidence for selecting the effective intervening measure to improve QOL of patients. Methods We retrospectively analyzed 25 advanced breast cancer patients who were treated with high-dose chemotherapy supported by autologous peripheral blood stem cells and 22 patients who received conventional-dose therapy as the control group. SF-12, the revised version of health survey scale SF-36 (MOS36-item short forum health survey) was used at three time points, T1(before the treatment), T2(before the 2nd cycle of high-dose chemotherapy and the 4th cycle of conventional-dose chemotherapy ) and T3(3 months after the treatment). T test was used for statistical analysis. Results At T2 point, 8 variables of QOL of patients treated with high-dose and conventional-dose chemotherapy were significantly decreased compared with those at T1 point. At T3 point, the vitality and social function were still significantly decreased compared with those at T1 point (P<0.05). Other variables had no significant difference. At T2 point, the general health, physical function, vitality and social function in the high-dose chemotherapy group were decreased significantly compared with those in the conventional-dose chemotherapy group (P<0.05). No significant difference was observed between the two groups at T1 or T3 points. Conclusion High-dose chemotherapy supported by autologous peripheral blood stem cells led to significant reduction of QOL of advanced breast cancer patients, especially the general health, physical function, vitality and social function. However, high-dose chemotherapy could shorten the treatment time and the patients could resume their normal lives faster.
  • [1]
    Wilcken N, Dear R. Chemotherapy in metastatic breast cancer: a summary of all randomised trials reported 2000-2007[J]. Eur J Cancer, 2008, 44(15): 2218-25.
    [2]
    Colomer R. Gemcitabine and paclitaxel in metastatic breast cancer: a review[J]. Oncology (Williston Park), 2004, 18(14 Suppl 12 ): 8-12.
    [3]
    Nitz UA, Mohrmann S, Fischer J, et al. Comparison of rapidly cycled tandem high-dose chemotherapy plus peripheral-blood stem-cell support versus dose-dense conventional chemotherapy for adjuvant treatment of high-risk breast cancer: results of a multicentre phase Ⅲ trial[J]. Lancet, 2005, 366(9501): 1935-44.
    [4]
    Biron P, Durand M, Roché H, et al. Pegase 03: a prospective randomized phase Ⅲ trial of FEC with or without high-dose thiotepa, cyclophosphamide and autologous stem cell transplantation in first-line treatment of metastatic breast cancer[J]. Bone Marrow Transplant, 2008, 41(6): 555-62.
    [5]
    Lotz JP, Curé H, Janvier M, et al. High-dose chemotherapy with haematopoietic stem cell transplantation for metastatic breast cancer patients: final results of the French multicentric randomised CMA/PEGASE 04 protocol[J]. Eur J Cancer, 2005, 41(1): 71-80.
    [6]
    Crump M, Gluck S, Tu D, et al. Randomized trial of high-dose chemotherapy with autologous peripheral-blood stem-cell support compared with standard-dose chemotherapy in women with metastatic breast cancer: NCIC MA.16[J]. J Clin Oncol, 2008, 26(1): 37 -43.
    [7]
    Partridge AH, Bunnell CA, Winer EP. Quality of life issues among women undergoing high-dose chemotherapy for breast cancer[J]. Breast Dis, 2001, 14: 41-50.
    [8]
    Buccheri G. Depressive reactions to lung cancer are common and often followed by a poor outcome[J].Eur Respir J, 1998, 11(1): 17 3-8.
    [9]
    Brandberg Y, Michelson H, Nilsson B, et al. Quality of life in women with breast cancer during the first year after random assignment to adjuvant treatment with marrow-supported high-dose chemotherapy with cyclophosphamide, thiotepa, and carboplatin or tailored therapy with Fluorouracil, epirubicin, and cyclophosphamide: Scandinavian Breast Group Study 9401[J]. J Clin Oncol, 20 03, 21(19): 3659-64.
    [10]
    Carlson LE, Koski T, Glück S. Longitudinal effects of high-dose chemotherapy and autologous stem cell transplantation on quality of life in the treatment of metastatic breast cancer[J]. Bone Marrow Transplant, 2001, 27(9): 989-98.
    [11]
    Prieto JM, Atala J, Blanch J, et al. Patient-rated emotional and physical functioning among hematologic cancer patients during hospitalization for stem-cell transplantation[J].Bone Marrow Transplant, 2005, 35(3): 307-14.
    [12]
    Andrykowski MA, Bishop MM, Hahn EA, et al. Long-term health-related quality of life, growth, and spiritual well-being after hematopoietic stem cell transplantation[J]. J Clin Oncol, 2005, 23 (3): 599-608.
    [13]
    Therasse P, Mauriac L, Welnicka-Jaskiewicz M, et al. Final results of a randomized Phase Ⅲ trial comparing cyclophosphamide, epirubicin, and fluorouracil with a dose-intensified epirubicin and cyclophosphamide + filgrastim as neoadjuvant treatment in locally advanced breast cancer: an EORTC-NCIC-SAKK multicenter study[J]. J Clin Oncol, 2003, 21(5): 843-50.
    [14]
    Morasso G, Costantini M, Baracco G, et al. Assessing psychological distress in cancer patients: validation of a self-administered questionnaire[J]. Oncology, 1996, 53(4): 295-302.
    [15]
    Danaher EH, Ferrans C, Verlen E, et al. Fatigue and physical activity in patients undergoing hematopoietic stem cell transplant[J]. Oncol Nurs Forum, 2006, 33(3): 614-24.
    [16]
    Yoo H, Lee K, Lee J, et al. Korean translation and validity of FACT-BMT version 4 and the quality of life in allogeneic bone marrow transplantation patients[J]. Qual Life Res, 2006, 15(3): 55 9-64.

Catalog

    Article views (1682) PDF downloads (376) Cited by()

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return